featured
-
When interrupting is good: genetic hiccups that protect against Huntington's disease
Multiple teams find small differences in the 'CAG repeat' bit of the Huntington's disease gene. They don't directly change the huntingtin protein, but do alter the age of symptom onset. What's behind this enigma and what does it mean for patients?
-
Huntington's disease therapeutics conference 2019 – Day 1
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
By Joel Stanton -
HDSA FAQ on the Roche/Genentech RG6042 program
HDSA's frequently asked questions factsheet about the huntingtin-lowering trial ASO program was so good we stole it (with permission)
By Dr Leora Fox -
Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
-
Switch off the genome editor when you’re done
CRISPR genome editing just got an off-switch. We cut through the hype to explore the technology in HD
-
Update confirms Huntington's disease 'gene silencing' trial on track
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
-
FDA approves a new drug for symptoms of Huntington's disease
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease
-
Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington's disease symptoms
Pfizer announces the 'Amaryllis' trial of a PDE-10 inhibitor drug failed to improve symptoms of HD
-
Sorry folks, the PRIDE-HD trial did NOT show that Pridopidine slows the progression of Huntington's disease
HDBuzz helps untangle some bold claims about the just-announced results of the PRIDE-HD trial of pridopidine in HD
-
Planting trees together: The 2016 Huntington's Disease Society of America Convention
HDBuzz summarizes the science from an unusually large and energized @HDSA convention in Baltimore